Navigation Links
Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009
Date:2/17/2009

Net cash provided by (used in) financing activities 1,410,770 (5,561,848) EFFECTS OF EXCHANGE RATE CHANGE IN CASH 369,646 513,427 INCREASE (DECREASE) IN CASH 28,184,062 (4,103,427) CASH, beginning of period 48,195,798 17,737,208 CASH, end of period $76,379,860 $13,633,781 GENESIS PHARMACEUTICALS ENTERPRISES, INC. AND SUBSIDIARIES RECONCILIATION OF NON-GAAP NET INCOME For Three Months Ended For Six Months Ended December 31 December 31 December 31 December 31 2008 2007 2008 2007 Net Income 5,399,186 5,153,463 8,532,670 8,388,455 Realized loss (income) on trading securities, net 418,134 (8,993) 1,459,656 (8,993) Amortization of debt discount and debt issuance costs related to convertible debetures 1,153,760 272,679 1,986,385 272,679 Adjusted Net Income 6,971,080 5,417,149 11,978,711 8,652,141 Adjusted Earnings Per Weighted Average Number of Shares $0.71 $0.56 $1.23 $1.46 Weighted Average Number of Shares 9,771,883 9,641,742 9,770,615 5,907,192 For more information, please contact: Genesis Pharmaceuticals Enterprises, Inc. Ms. Elsa Sung, CFO Tel: +1-954-727-8435 Email: elsasung@jiangbo.com Web: http://www.genesispharmaceuticals.com CCG Investor Relations, Inc. Mr. Crocker Coulson, President Tel: +1-646-213-1915 Email: '/>"/>
SOURCE Genesis Pharmaceuticals Enterprises, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related biology technology :

1. Genesis Pharmaceuticals Announces Conference Call to Discuss Results for its Second Quarter of FY 2009
2. Genesis HealthCare Promotes Wendy LaBate To Senior Vice President of Operations for the Northeast Area
3. AngioGenex Presents Data on its Id Targeted Anti-Angiogenesis Inhibitors at Two Scientific Conferences
4. ThermoGenesis Corp. to Announce Second Quarter Fiscal 2009 Results on February 4, 2009
5. Genesis Pharmaceuticals Appoints KPMG to Help Develop a SOX 404 Compliance Program
6. OmegaGenesis Announces Angiogenesis Application Collaboration
7. Cardiogenesis Announces Addition of Raymond W. Cohen to Board of Directors
8. Tissue Genesis Applies CE Mark to Its Adult Stem Cell Isolation System
9. Cardiogenesis Reports Third Quarter 2008 Results
10. ThermoGenesis Presentation at Rodman & Renshaw Conference
11. Genesis Pharmaceuticals Launches New Corporate Website
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... Iowa (PRWEB) September 02, 2014 Press ... of ways to take advantage of the people and ... the schedule below are available throughout the day. Additionally, ... requests with POET and DSM representatives as well as ... interview requests is appreciated. , Please remember to ...
(Date:9/2/2014)...  TransCelerate BioPharma Inc. ("TransCelerate") today announced that ... personal data in Clinical Study Reports (CSRs) that ... document describes an approach to apply when redacting ... related clinical trial documents, and is available ... TransCelerate CSR Redaction approach is to provide organizations ...
(Date:9/2/2014)... Quincy, MA (PRWEB) September 02, 2014 ... announced today the signage of a distribution agreement ... Azelis is now distributing Myriant’s bio-succinic acid in ... Kingdom and Ireland, targeting customers in the industrial ... chemical distribution powerhouse, Azelis offers a far-reaching chemical ...
(Date:9/2/2014)... SAN DIEGO , Sept. 2, 2014 ... announced that the U.S. Patent and Trademark Office (PTO) ... investigational medication being evaluated for weight loss. NB32 is ... bupropion SR. U.S. Patent No. 8,815,889 claims ... naltrexone and bupropion. The patent expires in 2024. If ...
Breaking Biology Technology:Press agenda for Project LIBERTY Grand Opening 2Press agenda for Project LIBERTY Grand Opening 3Press agenda for Project LIBERTY Grand Opening 4Press agenda for Project LIBERTY Grand Opening 5TransCelerate BioPharma Inc. Releases Recommended Approach for Protecting Personal Data in Clinical Study Reports 2TransCelerate BioPharma Inc. Releases Recommended Approach for Protecting Personal Data in Clinical Study Reports 3Myriant and Azelis Sign European Distribution Agreement for Bio-Succinic Acid 2Orexigen Expands NB32 Intellectual Property Portfolio With New U.S. Patent 2Orexigen Expands NB32 Intellectual Property Portfolio With New U.S. Patent 3Orexigen Expands NB32 Intellectual Property Portfolio With New U.S. Patent 4
... today announced positive results from its Phase IIa ... severely injured trauma patients with hemorrhagic shock causing ... given in addition to standard of care, was ... During hemorrhagic shock, inadequate perfusion of critical organs ...
... 31 Naurex Inc., a clinical stage company developing ... reported that its clinical stage candidate for the treatment ... been selected for inclusion on Windhover,s list of the ... were chosen by a committee that included Windhover Information, ...
... SEATTLE, Aug. 31 /PRNewswire-FirstCall/ - Oncothyreon Inc. (Nasdaq: ... of Julie M. Eastland as Chief Financial Officer ... 2010. Ms. Eastland,s responsibilities will include financial management, ... Eastland brings more than 25 years of financial ...
Cached Biology Technology:Sangart, Inc. Reports Positive Phase IIa Data for Novel Oxygen Therapeutic Agent MP4OX in Severe Trauma Patients 2Sangart, Inc. Reports Positive Phase IIa Data for Novel Oxygen Therapeutic Agent MP4OX in Severe Trauma Patients 3Naurex's Novel Antidepressant GLYX-13 Recognized as One of Windhover's Top 10 Neuroscience Projects to Watch 2Naurex's Novel Antidepressant GLYX-13 Recognized as One of Windhover's Top 10 Neuroscience Projects to Watch 3Naurex's Novel Antidepressant GLYX-13 Recognized as One of Windhover's Top 10 Neuroscience Projects to Watch 4Naurex's Novel Antidepressant GLYX-13 Recognized as One of Windhover's Top 10 Neuroscience Projects to Watch 5ONCOTHYREON APPOINTS JULIE M. EASTLAND AS CHIEF FINANCIAL OFFICER 2
(Date:9/2/2014)... limestone is well known as a result of ... (for example, Archaeopteryx). Now, for the first time, ... equivalent of these outcrops - discoveries which include ... treader. , Despite the abundance of fossils in ... obtained from the Late Kimmeridgian equivalents of these ...
(Date:9/1/2014)... has improved steadily in recent yearsspurred in large part ... poor and disparities continue to widen among socioeconomic and ... School of Public Health (HSPH). , "The study provides ... efforts by many groups and individuals to improve U.S. ... indicates that these efforts need to be expanded," said ...
(Date:9/1/2014)... EDT) It may be possible to train the ... foods, according to new research by scientists at the ... (USDA HNRCA) at Tufts University and at Massachusetts General ... & Diabetes , a brain scan study in adult ... reverse the addictive power of unhealthy food while also ...
Breaking Biology News(10 mins):Exceptionally well preserved insect fossils from the Rhône Valley 2Quality of US diet shows modest improvement, but overall remains poor 2Quality of US diet shows modest improvement, but overall remains poor 3Training your brain to prefer healthy foods 2
... inbreeding is a threat against the viabi lity of ... in the new journal PLoS ONE now demonstrates that ... expected. The results show that it is the most ... breeding population. An important consequence of this action of ...
... has discovered that some stealthy mammals have been doing something ... water. , The results of the research by Vanderbilt's Kenneth ... the science journal Nature. He became curious when he observed ... bubbles while swimming. , "This came as a ...
... which can become less effective over time, might retain ... second drug, according to new research in mice conducted ... of the National Institutes of Health, and their partners. ... of Cancer Cell*. , Tamoxifen has been used successfully ...
Cached Biology News:Wolves are suffering less from inbreeding than expected 2Contrary to common wisdom, scientist discovers some mammals can smell objects under water 2Contrary to common wisdom, scientist discovers some mammals can smell objects under water 3Restoring tamoxifen sensitivity in resistant breast cancer cells 2
Taq DNA polymerase, 10,000U...
... AmpliTaq DNA Polymerase is the ... PCR process, a testimony to its overall ... profile makes it ideal for PCR applications. ... guarantee reproducible results. ,, AmpliTaq DNA ...
Taq DNA Polymerase (T. aquaticus), 4 x 250 units. For PCR and other procedures requiring DNA polymerase activity at elevated temperatures. Category: Nucleotides & Enzymes & Biochemicals, Modifying En...
... GCpro Taq DNA Polymerase is a versatile ... for all PCR applications. GCpro Taq DNA ... expressed in E. coli, containing the DNA ... enzyme includes a highly processive 5'-3' DNA ...
Biology Products: